Cargando…

Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution

BACKGROUND: The status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated. METHODS: The status of 10 targeted genes was evaluated by next‐generation sequencing (NGS) in 884 non‐small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dan, Ding, Li, Ran, Wenwen, Huang, Yan, Li, Guangqi, Wang, Chengqin, Xiao, Yujing, Wang, Xiaonan, Lin, Dongliang, Xing, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471050/
https://www.ncbi.nlm.nih.gov/pubmed/32729257
http://dx.doi.org/10.1111/1759-7714.13577
_version_ 1783578700780929024
author Li, Dan
Ding, Li
Ran, Wenwen
Huang, Yan
Li, Guangqi
Wang, Chengqin
Xiao, Yujing
Wang, Xiaonan
Lin, Dongliang
Xing, Xiaoming
author_facet Li, Dan
Ding, Li
Ran, Wenwen
Huang, Yan
Li, Guangqi
Wang, Chengqin
Xiao, Yujing
Wang, Xiaonan
Lin, Dongliang
Xing, Xiaoming
author_sort Li, Dan
collection PubMed
description BACKGROUND: The status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated. METHODS: The status of 10 targeted genes was evaluated by next‐generation sequencing (NGS) in 884 non‐small cell lung cancer (NSCLC) patients. The relationship between gene alterations and clinicopathological characters was analyzed. RESULTS: Overall, 684 (77.4%) patients harbored gene alterations, and EGFR (510, 57.7%) was found to be the most common type of mutation followed by KRAS (91, 10.3%), HER2 (38, 4.3%), PIK3CA (32, 3.6%), ALK (21, 2.4%), BRAF (10, 1.1%), ROS1 (5, 0.6%), RET (5, 0.6%), MET (4, 0.5%) and NRAS (1, 0.1%). Gene alterations were more frequent in females, non‐smokers and adenocarcinoma (P < 0.001). EGFR mutations were associated with women, non‐smokers, normal level of serum tumor markers, and adenocarcinoma (P < 0.001). Patients without lymph node metastasis (P = 0.012), or early stage disease (P < 0.001) exhibited a higher EGFR mutation rate. KRAS mutations tended to arise in men (P < 0.001), smokers (P < 0.001) and patients with higher levels of serum tumor markers (P = 0.048). A mucus‐producing component was associated with KRAS (P < 0.001), ROS1 (P = 0.033) and ALK (P < 0.001) alterations. ALK and ROS1 rearrangements were more frequent in micropapillary structures (P = 0.004, P = 0.012). BRAF mutation was associated with advanced disease patients and micropapillary structure (P < 0.001). PIK3CA mutation was more likely to be found in elderly patients (P = 0.014). Some patients had synchronous gene alterations, including EGFR/PIK3CA, EGFR/HER2, HER2/KRAS, EGFR/KRAS, EGFR/ROS1, EGFR/NRAS, KRAS/PIK3CA, KRAS/PIK3CA/HER2. CONCLUSIONS: Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration had unique clinicopathological characteristics. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: This study revealed the frequency and distribution of 10 targeted gene abnormalities and their association with clinicopathological parameters of Chinese non‐small cell lung cancer (NSCLC) patients in eastern China. WHAT THIS STUDY ADDS: Some rare synchronous mutations were detected in our study by next‐generation sequencing (NGS).
format Online
Article
Text
id pubmed-7471050
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-74710502020-09-11 Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution Li, Dan Ding, Li Ran, Wenwen Huang, Yan Li, Guangqi Wang, Chengqin Xiao, Yujing Wang, Xiaonan Lin, Dongliang Xing, Xiaoming Thorac Cancer Original Articles BACKGROUND: The status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated. METHODS: The status of 10 targeted genes was evaluated by next‐generation sequencing (NGS) in 884 non‐small cell lung cancer (NSCLC) patients. The relationship between gene alterations and clinicopathological characters was analyzed. RESULTS: Overall, 684 (77.4%) patients harbored gene alterations, and EGFR (510, 57.7%) was found to be the most common type of mutation followed by KRAS (91, 10.3%), HER2 (38, 4.3%), PIK3CA (32, 3.6%), ALK (21, 2.4%), BRAF (10, 1.1%), ROS1 (5, 0.6%), RET (5, 0.6%), MET (4, 0.5%) and NRAS (1, 0.1%). Gene alterations were more frequent in females, non‐smokers and adenocarcinoma (P < 0.001). EGFR mutations were associated with women, non‐smokers, normal level of serum tumor markers, and adenocarcinoma (P < 0.001). Patients without lymph node metastasis (P = 0.012), or early stage disease (P < 0.001) exhibited a higher EGFR mutation rate. KRAS mutations tended to arise in men (P < 0.001), smokers (P < 0.001) and patients with higher levels of serum tumor markers (P = 0.048). A mucus‐producing component was associated with KRAS (P < 0.001), ROS1 (P = 0.033) and ALK (P < 0.001) alterations. ALK and ROS1 rearrangements were more frequent in micropapillary structures (P = 0.004, P = 0.012). BRAF mutation was associated with advanced disease patients and micropapillary structure (P < 0.001). PIK3CA mutation was more likely to be found in elderly patients (P = 0.014). Some patients had synchronous gene alterations, including EGFR/PIK3CA, EGFR/HER2, HER2/KRAS, EGFR/KRAS, EGFR/ROS1, EGFR/NRAS, KRAS/PIK3CA, KRAS/PIK3CA/HER2. CONCLUSIONS: Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration had unique clinicopathological characteristics. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: This study revealed the frequency and distribution of 10 targeted gene abnormalities and their association with clinicopathological parameters of Chinese non‐small cell lung cancer (NSCLC) patients in eastern China. WHAT THIS STUDY ADDS: Some rare synchronous mutations were detected in our study by next‐generation sequencing (NGS). John Wiley & Sons Australia, Ltd 2020-07-30 2020-09 /pmc/articles/PMC7471050/ /pubmed/32729257 http://dx.doi.org/10.1111/1759-7714.13577 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Li, Dan
Ding, Li
Ran, Wenwen
Huang, Yan
Li, Guangqi
Wang, Chengqin
Xiao, Yujing
Wang, Xiaonan
Lin, Dongliang
Xing, Xiaoming
Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
title Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
title_full Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
title_fullStr Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
title_full_unstemmed Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
title_short Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
title_sort status of 10 targeted genes of non‐small cell lung cancer in eastern china: a study of 884 patients based on ngs in a single institution
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471050/
https://www.ncbi.nlm.nih.gov/pubmed/32729257
http://dx.doi.org/10.1111/1759-7714.13577
work_keys_str_mv AT lidan statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT dingli statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT ranwenwen statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT huangyan statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT liguangqi statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT wangchengqin statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT xiaoyujing statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT wangxiaonan statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT lindongliang statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution
AT xingxiaoming statusof10targetedgenesofnonsmallcelllungcancerineasternchinaastudyof884patientsbasedonngsinasingleinstitution